|
CA2853829C
(en)
|
2011-07-22 |
2023-09-26 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
JP2014531908A
(ja)
|
2011-10-14 |
2014-12-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
構造アッセンブリによる配列決定
|
|
ES2991004T3
(es)
|
2011-12-22 |
2024-12-02 |
Harvard College |
Métodos para la detección de analitos
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
RU2018109507A
(ru)
|
2012-02-24 |
2019-02-28 |
Фред Хатчинсон Кэнсер Рисерч Сентер |
Композиции и способы лечения гемоглобинопатии
|
|
GB2537000C
(en)
|
2012-05-25 |
2019-10-09 |
Univ California |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
SG11201500852WA
(en)
|
2012-08-29 |
2015-04-29 |
Sangamo Biosciences Inc |
Methods and compositions for treatment of a genetic condition
|
|
EP4556564A3
(en)
*
|
2012-10-23 |
2025-09-03 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
AU2013352156B2
(en)
|
2012-11-27 |
2018-12-06 |
Children's Medical Center Corporation |
Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction
|
|
CA2891347C
(en)
|
2012-12-06 |
2018-02-27 |
Sigma-Aldrich Co. Llc |
Crispr-based genome modification and regulation
|
|
IL239317B
(en)
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
US9970024B2
(en)
|
2012-12-17 |
2018-05-15 |
President And Fellows Of Harvard College |
RNA-guided human genome engineering
|
|
EP3578666A1
(en)
|
2013-03-12 |
2019-12-11 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
|
AU2014235794A1
(en)
|
2013-03-14 |
2015-10-22 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
|
KR102874079B1
(ko)
|
2013-03-15 |
2025-10-22 |
더 제너럴 하스피탈 코포레이션 |
Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
|
|
CN115261411A
(zh)
|
2013-04-04 |
2022-11-01 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
|
WO2014186585A2
(en)
*
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
WO2014197568A2
(en)
|
2013-06-04 |
2014-12-11 |
President And Fellows Of Harvard College |
Rna-guideded transcriptional regulation
|
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
|
EP3620524A1
(en)
|
2013-06-17 |
2020-03-11 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
CN105793425B
(zh)
|
2013-06-17 |
2021-10-26 |
布罗德研究所有限公司 |
使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
AU2014281028B2
(en)
|
2013-06-17 |
2020-09-10 |
Massachusetts Institute Of Technology |
Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
|
|
WO2015006498A2
(en)
*
|
2013-07-09 |
2015-01-15 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
JP6718813B2
(ja)
|
2013-07-10 |
2020-07-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質
|
|
US10563225B2
(en)
|
2013-07-26 |
2020-02-18 |
President And Fellows Of Harvard College |
Genome engineering
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
CN111218447B
(zh)
|
2013-11-07 |
2024-10-11 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
WO2015073683A2
(en)
*
|
2013-11-13 |
2015-05-21 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
|
EP3071695A2
(en)
*
|
2013-11-18 |
2016-09-28 |
Crispr Therapeutics AG |
Crispr-cas system materials and methods
|
|
US10787684B2
(en)
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
|
CN118813621A
(zh)
|
2013-12-12 |
2024-10-22 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
US20150166982A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
|
WO2015089419A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
US9963689B2
(en)
|
2013-12-31 |
2018-05-08 |
The Regents Of The University Of California |
Cas9 crystals and methods of use thereof
|
|
SG10201805815YA
(en)
|
2014-01-08 |
2018-08-30 |
Harvard College |
Rna-guided gene drives
|
|
CA2939621C
(en)
|
2014-02-13 |
2019-10-15 |
Takara Bio Usa, Inc. |
Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US9938521B2
(en)
|
2014-03-10 |
2018-04-10 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
|
WO2015148860A1
(en)
*
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta-thalassemia
|
|
US20170173083A1
(en)
*
|
2014-03-26 |
2017-06-22 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
|
|
CN106794260B
(zh)
|
2014-04-25 |
2021-02-23 |
儿童医疗中心有限公司 |
治疗血红蛋白病的组合物和方法
|
|
WO2016007839A1
(en)
|
2014-07-11 |
2016-01-14 |
President And Fellows Of Harvard College |
Methods for high-throughput labelling and detection of biological features in situ using microscopy
|
|
EP3177718B1
(en)
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
US11071289B2
(en)
*
|
2014-08-14 |
2021-07-27 |
Biocytogen Boston Corp |
DNA knock-in system
|
|
IL292574A
(en)
|
2014-09-07 |
2022-06-01 |
Selecta Biosciences Inc |
Methods and compositions for attenuating anti-viral transfer vector immune responses
|
|
CN113699113A
(zh)
*
|
2014-09-16 |
2021-11-26 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
CN113016623A
(zh)
|
2014-09-26 |
2021-06-25 |
谱赛科美国股份有限公司 |
用于甜菊的单核苷酸多态性(snp)标志物
|
|
EP3215623A4
(en)
|
2014-11-06 |
2018-09-26 |
President and Fellows of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
KR102763527B1
(ko)
|
2014-12-03 |
2025-02-05 |
애질런트 테크놀로지스, 인크. |
화학적 변형을 갖는 가이드 rna
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3230452B1
(en)
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
|
US20180002379A1
(en)
*
|
2015-01-21 |
2018-01-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
AU2016211671B2
(en)
|
2015-01-26 |
2022-05-26 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
SG11201706766WA
(en)
|
2015-02-23 |
2017-09-28 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
EP3262173A2
(en)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
|
CA2981715A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
|
US10155938B2
(en)
*
|
2015-04-14 |
2018-12-18 |
City Of Hope |
Coexpression of CAS9 and TREX2 for targeted mutagenesis
|
|
CN104805118A
(zh)
*
|
2015-04-22 |
2015-07-29 |
扬州大学 |
一种苏禽黄鸡胚胎干细胞特定基因进行靶向敲除方法
|
|
EP3292219B9
(en)
*
|
2015-05-04 |
2022-05-18 |
Ramot at Tel-Aviv University Ltd. |
Methods and kits for fragmenting dna
|
|
US11572543B2
(en)
*
|
2015-05-08 |
2023-02-07 |
The Children's Medical Center. Corporation |
Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction
|
|
CA2988854A1
(en)
|
2015-05-08 |
2016-11-17 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
|
JP7030522B2
(ja)
*
|
2015-05-11 |
2022-03-07 |
エディタス・メディシン、インコーポレイテッド |
幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
|
|
MX382223B
(es)
*
|
2015-05-12 |
2025-03-13 |
Sangamo Therapeutics Inc |
Regulacion de expresion genica mediada por nucleasa.
|
|
KR102796744B1
(ko)
|
2015-06-09 |
2025-04-15 |
에디타스 메디신, 인코포레이티드 |
이식의 개선을 위한 crispr/cas-관련 방법 및 조성물
|
|
WO2016205703A1
(en)
*
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for genomic editing
|
|
AU2016278959A1
(en)
|
2015-06-17 |
2018-01-18 |
The Uab Research Foundation |
CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
EP3341477B1
(en)
|
2015-08-28 |
2022-03-23 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9897378B2
(en)
|
2015-10-08 |
2018-02-20 |
Nyc Designed Inspirations Llc |
Cosmetic makeup sponge/blender container
|
|
SG11201803173VA
(en)
|
2015-10-23 |
2018-05-30 |
Harvard College |
Nucleobase editors and uses thereof
|
|
ES2908041T3
(es)
*
|
2015-10-27 |
2022-04-27 |
Childrens Hospital Med Ct |
Uso de inhibidores de MAPK para reducir la pérdida de células madre hematopoyéticas durante el cultivo ex vivo y la manipulación genética
|
|
HK1252878A1
(zh)
|
2015-11-03 |
2019-06-06 |
President And Fellows Of Harvard College |
用於含有基质的三维核酸的体积成像的方法和设备
|
|
EP3371306B8
(en)
*
|
2015-11-04 |
2023-02-22 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
|
PT3371314T
(pt)
|
2015-11-04 |
2023-08-31 |
Fate Therapeutics Inc |
Modificação genómica de células pluripotentes
|
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
US20190010495A1
(en)
*
|
2015-12-28 |
2019-01-10 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
RU2021114137A
(ru)
|
2016-01-27 |
2021-05-25 |
Онкорус, Инк. |
Онколитические вирусные векторы и их применение
|
|
WO2017147278A1
(en)
|
2016-02-25 |
2017-08-31 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by crispr/cas9 technology
|
|
EP3430142A1
(en)
*
|
2016-03-14 |
2019-01-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
SI3445388T1
(sl)
*
|
2016-04-18 |
2024-07-31 |
Vertex Pharmaceuticals Incorporated |
Materiali in metode za zdravljenje hemoglobinopatij
|
|
JP7259182B2
(ja)
|
2016-04-25 |
2023-04-18 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ｉｎ ｓｉｔｕ分子検出のためのハイブリダイゼーション連鎖反応法
|
|
WO2017191503A1
(en)
*
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
AU2017301609A1
(en)
*
|
2016-07-25 |
2019-02-21 |
Bluebird Bio, Inc. |
BCL11A homing endonuclease variants, compositions, and methods of use
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
CN106244555A
(zh)
*
|
2016-08-23 |
2016-12-21 |
广州医科大学附属第三医院 |
一种提高基因打靶的效率的方法及β‑球蛋白基因位点的碱基原位修复方法
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
CA3035455A1
(en)
|
2016-09-08 |
2018-03-15 |
Bluebird Bio, Inc. |
Pd-1 homing endonuclease variants, compositions, and methods of use
|
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
|
JP7175277B2
(ja)
|
2017-01-27 |
2022-11-18 |
チルドレンズ ホスピタル メディカル センター |
造血幹細胞の生着活性を向上させる方法
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
US12390514B2
(en)
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
CN111031790A
(zh)
|
2017-04-20 |
2020-04-17 |
E开创生物技术股份有限公司 |
产生基因修改的动物的方法
|
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
|
WO2018200597A1
(en)
*
|
2017-04-24 |
2018-11-01 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Homology directed repair compositions for the treatment of hemoglobinopathies
|
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
CA3063449A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
|
US11788087B2
(en)
|
2017-05-25 |
2023-10-17 |
The Children's Medical Center Corporation |
BCL11A guide delivery
|
|
US12139720B2
(en)
*
|
2017-06-02 |
2024-11-12 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant lentiviral vector for stem cell- based gene therapy of sickle cell disorder
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
US11612625B2
(en)
|
2017-07-26 |
2023-03-28 |
Oncorus, Inc. |
Oncolytic viral vectors and uses thereof
|
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
WO2019070974A1
(en)
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
|
KR20200086670A
(ko)
|
2017-10-13 |
2020-07-17 |
셀렉타 바이오사이언시즈, 인크. |
항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물
|
|
AU2018352592C1
(en)
|
2017-10-16 |
2025-09-25 |
Beam Therapeutics, Inc. |
Uses of adenosine base editors
|
|
US20210180091A1
(en)
*
|
2017-10-26 |
2021-06-17 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
|
CN109722414A
(zh)
*
|
2017-10-27 |
2019-05-07 |
博雅辑因（北京）生物科技有限公司 |
一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基
|
|
MX2020005849A
(es)
*
|
2017-12-05 |
2020-11-06 |
Vertex Pharma |
Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
|
|
EP3724214A4
(en)
|
2017-12-15 |
2021-09-01 |
The Broad Institute Inc. |
SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
|
|
EP3749768A1
(en)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
|
WO2019150196A1
(en)
|
2018-02-05 |
2019-08-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
KR20200139679A
(ko)
|
2018-02-26 |
2020-12-14 |
안톨알엑스, 인크. |
면역관용성 리포솜 및 그의 사용 방법
|
|
WO2019178426A1
(en)
|
2018-03-14 |
2019-09-19 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
US10968257B2
(en)
|
2018-04-03 |
2021-04-06 |
The Broad Institute, Inc. |
Target recognition motifs and uses thereof
|
|
WO2019204226A1
(en)
|
2018-04-16 |
2019-10-24 |
University Of Massachusetts |
Compositions and methods for improved gene editing
|
|
WO2019210216A2
(en)
*
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase
|
|
US12350284B2
(en)
|
2018-05-02 |
2025-07-08 |
The Children's Medical Center Corporation |
BCL11A microRNAs for treating hemoglobinopathies
|
|
CA3100019A1
(en)
|
2018-05-11 |
2019-11-14 |
Beam Therapeutics Inc. |
Methods of substituting pathogenic amino acids using programmable base editor systems
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
AU2019287720B2
(en)
|
2018-06-14 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
CD79A chimeric antigen receptors
|
|
SG11202101576UA
(en)
|
2018-08-18 |
2021-03-30 |
Harvard College |
In situ gene editing
|
|
US12421507B2
(en)
|
2018-08-20 |
2025-09-23 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of CRISPR-CAS9
|
|
US20200102563A1
(en)
*
|
2018-10-02 |
2020-04-02 |
Exosome Therapeutics, Inc. |
Exosome loaded therapeutics for treating sickle cell disease
|
|
US12312584B2
(en)
|
2018-10-02 |
2025-05-27 |
Exosome Therapeutics, Inc. |
cGMP exosome loaded therapeutics for treating sickle cell disease
|
|
WO2020076976A1
(en)
|
2018-10-10 |
2020-04-16 |
Readcoor, Inc. |
Three-dimensional spatial molecular indexing
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
EP3887521A1
(en)
*
|
2018-11-29 |
2021-10-06 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
US12404500B2
(en)
|
2018-12-10 |
2025-09-02 |
Novo Nordisk A/S |
Homing endonuclease variants
|
|
CN113544266A
(zh)
|
2018-12-17 |
2021-10-22 |
博德研究所 |
Crispr相关转座酶系统和其使用方法
|
|
US12264323B2
(en)
|
2018-12-17 |
2025-04-01 |
The Broad Institute, Inc. |
CRISPR CPF1 direct repeat variants
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
AU2020223060B2
(en)
*
|
2019-02-13 |
2023-04-13 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
|
GB2601617B
(en)
|
2019-03-19 |
2024-02-21 |
Broad Inst Inc |
Methods and compositions for editing nucleotide sequences
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
CN110042124A
(zh)
*
|
2019-04-25 |
2019-07-23 |
国家卫生健康委科学技术研究所 |
基因组碱基编辑增加人红细胞中胎儿血红蛋白水平的试剂盒及应用
|
|
JP2022531269A
(ja)
*
|
2019-04-30 |
2022-07-06 |
博雅▲輯▼因（北京）生物科技有限公司 |
異常ヘモグロビン症の治療の有効性を予測するための方法
|
|
CN111939271A
(zh)
*
|
2019-04-30 |
2020-11-17 |
博雅辑因（北京）生物科技有限公司 |
一种血红蛋白病治疗有效性预测方法
|
|
CN114206396A
(zh)
|
2019-05-28 |
2022-03-18 |
西莱克塔生物科技公司 |
用于减弱抗病毒转移载体免疫应答的方法和组合物
|
|
CN114072518B
(zh)
*
|
2019-06-28 |
2024-06-21 |
Asc治疗公司 |
用于治疗地中海贫血或镰状细胞病的方法和组合物
|
|
EP4038190A1
(en)
|
2019-10-03 |
2022-08-10 |
Artisan Development Labs, Inc. |
Crispr systems with engineered dual guide nucleic acids
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
WO2021077000A1
(en)
|
2019-10-16 |
2021-04-22 |
The Broad Institute, Inc. |
Engineered muscle targeting compositions
|
|
EP4058586A4
(en)
*
|
2019-11-15 |
2024-04-10 |
The Board of Trustees of the Leland Stanford Junior University |
Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cells
|
|
CN112979823B
(zh)
*
|
2019-12-18 |
2022-04-08 |
华东师范大学 |
一种用于治疗和/或预防β血红蛋白病的产品及融合蛋白
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
JP2023526007A
(ja)
*
|
2020-05-13 |
2023-06-20 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
β－ヘモグロビン異常症の処置のための塩基編集アプローチ
|
|
CN116157514A
(zh)
*
|
2020-06-04 |
2023-05-23 |
埃门多生物公司 |
新颖omni-59、61、67、76、79、80、81和82crispr核酸酶
|
|
WO2022003568A1
(en)
|
2020-06-30 |
2022-01-06 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
US20220049303A1
(en)
|
2020-08-17 |
2022-02-17 |
Readcoor, Llc |
Methods and systems for spatial mapping of genetic variants
|
|
CN116157517A
(zh)
*
|
2020-09-04 |
2023-05-23 |
国立大学法人广岛大学 |
目标dna的编辑方法、编辑了目标dna的细胞的制备方法及用于它们的dna编辑系统
|
|
JP2024503249A
(ja)
*
|
2020-12-21 |
2024-01-25 |
２セブンティ バイオ インコーポレイテッド |
部位特異的変異導入のための組成物及び方法
|
|
AU2022227650A1
(en)
|
2021-02-25 |
2023-10-12 |
Celyntra Therapeutics Sa |
Compositions and methods for targeting, editing, or modifying genes
|
|
EP4304633A1
(en)
|
2021-03-12 |
2024-01-17 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
|
US20250179481A1
(en)
|
2021-06-01 |
2025-06-05 |
Celyntra Therapeutics Sa |
Compositions and methods for targeting, editing, or modifying genes
|
|
CN113481184A
(zh)
*
|
2021-08-06 |
2021-10-08 |
北京大学 |
融合蛋白以及其使用方法
|
|
JP2024534945A
(ja)
|
2021-09-10 |
2024-09-26 |
アジレント・テクノロジーズ・インク |
化学修飾を有するプライム編集のためのガイドｒｎａ
|
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
|
CN114457119B
(zh)
*
|
2022-04-11 |
2022-08-12 |
中吉智药(南京)生物技术有限公司 |
慢病毒载体在制备治疗β-地中海贫血药物中的应用
|
|
EP4273242A1
(en)
*
|
2022-05-03 |
2023-11-08 |
ETH Zurich |
Crispr-based modification of human hbd gene
|
|
CN117427169A
(zh)
*
|
2023-10-24 |
2024-01-23 |
中国医学科学院基础医学研究所 |
同时破坏HBB竞争和HBG表观沉默在治疗β-血红蛋白病中的应用
|